- Research works
- 20 ▲ 106% vs 2013–17
- Citations
- 582 28.6 per fractional work
- Top-10% rate
- 9.1% record average 16.5%
- Open access
- 56% world 28%
Not ranked overall: Jeuk (South Korea) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 10.6×. Every wedge is a field page.
Which keywords describe research at Jeuk (South Korea)?
By fractional works in all years, weighted toward what it does more of than the world: Targeted Therapy, Tumor Microenvironment, Clinical Trials, Cancer, Immunotherapy, Chemotherapy, ALK Inhibitors and EGFR Mutations.
- Tumor Targeting
- Gene Therapy
- Gene Expression
- Mutational Signatures
- Cancer Genomics
- Metabolism
- PD-1 and PD-L1
- EGFR Mutations
- Immunotherapy
- Cancer
- Tumor Microenvironment
- Targeted Therapy
- Clinical Trials
- Chemotherapy
- ALK Inhibitors
- Immune Checkpoint Blockade
- Inflammation
- Genomic Instability
- Cancer Immunotherapy
- Tumor Regression
- Immunity
- Radiotherapy
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 22 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 22 words, with their numbers
- Targeted Therapy4▲ 99×4 topics
- Tumor Microenvironment4▲ 51×6 topics
- Clinical Trials3▲ 23×2 topics
- Cancer3▲ 10×13 topics
- Chemotherapy3▲ 19×9 topics
- Immunotherapy3▲ 21×7 topics
- ALK Inhibitors2▲ 216×1 topic
- EGFR Mutations2▲ 216×1 topic
- Immune Checkpoint Blockade2▲ 150×1 topic
- PD-1 and PD-L12▲ 150×1 topic
- Inflammation2▲ 3.3×5 topics
- Metabolism2▲ 12×4 topics
- Genomic Instability1▲ 52×2 topics
- Cancer Genomics1▲ 116×1 topic
- Cancer Immunotherapy1▲ 45×3 topics
- Mutational Signatures1▲ 116×1 topic
- Tumor Regression1▲ 73×2 topics
- Gene Expression1▲ 9.8×6 topics
- Immunity1▲ 18×2 topics
- Gene Therapy1▲ 21×3 topics
- Radiotherapy1▲ 14×5 topics
- Tumor Targeting1▲ 42×2 topics
Which research topics does Jeuk (South Korea) publish most on?
By volume in 2022–2025: Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers and Immune cells in cancer.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 1 works
- 2 Cancer Genomics and Diagnostics Cancer Research 1 works
- 3 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 4 Immune cells in cancer Immunology 1 works
- 5 Ferroptosis and cancer prognosis Pulmonary and Respiratory Medicine 0 works
- 6 Single-cell and spatial transcriptomics Molecular Biology 0 works
- 7 Radiomics and Machine Learning in Medical Imaging Radiology, Nuclear Medicine and Imaging 0 works
- 8 Cancer Cells and Metastasis Oncology 0 works
- 9 Innovative Microfluidic and Catalytic Techniques Innovation Biomedical Engineering 0 works
- 10 3D Printing in Biomedical Research Biomedical Engineering 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Jeuk (South Korea)'s research output changed?
Output in 2018–2022 was 106% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Gumi
- Kumoh National Institute of Technology
- Kyungwoon University
- Gumi University
- Gumi Electronics & Information Technology Research Institute (South Korea)
- U-Tel (South Korea)
- Bexel (South Korea)
- Wonbiogen (South Korea)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.